ACRV Acrivon Therapeutics
- 7.720
- +0.150+1.98%
- 8.020
- +0.300+3.89%
Acrivon Therapeutics News
Acrivon Therapeutics to Present at the Jefferies Global Healthcare Conference
WATERTOWN, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. ("Acrivon" or "Acrivon Therapeutics") (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision o
JMP Securities Maintains Acrivon Therapeutics(ACRV.US) With Buy Rating, Maintains Target Price $17
JMP Securities analyst Silvan Tuerkcan maintains $Acrivon Therapeutics(ACRV.US)$ with a buy rating, and maintains the target price at $17.According to TipRanks data, the analyst has a success rate of
Acrivon Therapeutics: A Buy Rating on Strong Clinical and Financial Prospects
Has Acrivon Therapeutics, Inc. (ACRV) Outpaced Other Medical Stocks This Year?
Bank of Montreal, Canada: Reiterated the Acrivon Therapeutics (ACRV.US) rating, adjusted from superior to superior market rating, and adjusted the target price from $25.00 to $25.00.
Bank of Montreal, Canada: Reiterated the Acrivon Therapeutics (ACRV.US) rating, adjusted from superior to superior market rating, and adjusted the target price from $25.00 to $25.00.
BMO Capital Reiterates Outperform on Acrivon Therapeutics, Maintains $25 Price Target
BMO Capital analyst Etzer Darout reiterates Acrivon Therapeutics with a Outperform and maintains $25 price target.
Analysts Offer Insights on Healthcare Companies: Acrivon Therapeutics, Inc. (ACRV), Arcutis Biotherapeutics (ARQT) and TruBridge (TBRG)
Acrivon Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Acrivon Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Acrivon Therapeutics Price Target Raised to $22.00/Share From $20.00 by HC Wainwright & Co.
Acrivon Therapeutics Price Target Raised to $22.00/Share From $20.00 by HC Wainwright & Co.
HC Wainwright & Co. : The Acrivon Therapeutics (ACRV.US) rating was maintained, adjusted from buy to buy rating, and the target price was adjusted from $20.00 to $22.00.
HC Wainwright & Co. : The Acrivon Therapeutics (ACRV.US) rating was maintained, adjusted from buy to buy rating, and the target price was adjusted from $20.00 to $22.00.
HC Wainwright & Co. Maintains Buy on Acrivon Therapeutics, Raises Price Target to $22
HC Wainwright & Co. analyst Emily Bodnar maintains Acrivon Therapeutics (NASDAQ:ACRV) with a Buy and raises the price target from $20 to $22.
Analysts Offer Insights on Healthcare Companies: Shattuck Labs (STTK) and Acrivon Therapeutics, Inc. (ACRV)
Acrivon Therapeutics (ACRV.US): The 2024 Q1 financial report achieved revenue of $0, previous value of $0; earnings per share were -0.73 dollars, previous value was -0.58 dollars, and expected value was -0.84 dollars.
Acrivon Therapeutics (ACRV.US): The 2024 Q1 financial report achieved revenue of $0, previous value of $0; earnings per share were -0.73 dollars, previous value was -0.58 dollars, and expected value was -0.84 dollars.
Acrivon Therapeutics Q1 EPS $(0.73) Beats $(0.84) Estimate
Acrivon Therapeutics (NASDAQ:ACRV) reported quarterly losses of $(0.73) per share which beat the analyst consensus estimate of $(0.84) by 13.1 percent. This is a 25.86 percent decrease over losses of
Acrivon Therapeutics 1Q Loss/Shr 73c >ACRV
Acrivon Therapeutics 1Q Loss/Shr 73c >ACRV
Acrivon Therapeutics 1Q Research and Development Expenses $11.5M >ACRV
Acrivon Therapeutics 1Q Research and Development Expenses $11.5M >ACRV
Press Release: Acrivon Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights
Acrivon Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights WATERTOWN, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. ("Acrivon" or "Acrivon Therapeu
Acrivon Therapeutics | 10-Q: Quarterly report
Acrivon Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights
WATERTOWN, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. ("Acrivon" or "Acrivon Therapeutics") (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision on
While Institutions Own 26% of Acrivon Therapeutics, Inc. (NASDAQ:ACRV), Private Equity Firms Are Its Largest Shareholders With 50% Ownership
Analysis
Price Target
No Data
